The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy. (April 2020)

• Record Type: Journal Article
• Authors: Wilcox, Karen S.; West, Peter J.; Metcalf, Cameron S.
• Is Part Of: Neuropharmacology. Volume 166(2020)
• Publication Date: 2020-04
• Subjects: Antiseizure drug (ASD) -- Pharmacoresistant epilepsy -- Animal model -- Epilepsy Therapy Screening Program (ETSP); Neuropsychopharmacology -- Periodicals; Autonomic Agents -- Periodicals; Neuropsychopharmacologie -- Périodiques; Neuropsychopharmacology; Periodicals; Electronic journals; 615.78
• DOI: 10.1016/j.neuropharm.2019.107811
• Languages: English
• ISSNs: 0028-3908

Abstract

Abstract: The Epilepsy Therapy Screening Program (ETSP), formerly known as the Anticonvulsant Screening Program (ASP), has played an important role in the preclinical evaluation of many of the antiseizure drugs (ASDs) that have been approved by the FDA and thus made available for the treatment of seizures. Recent changes to the animal models used at the contract site of the ETSP at the University of Utah have been implemented in an attempt to better model the unmet clinical needs of people with pharmacoresistant epilepsy and thus identify improved therapies. In this review, we describe the changes that have occurred over the last several years in the screening approach used at the contract site and, in particular, detail the pharmacology associated with several of the animal models and assays that are either new to the program or have been recently characterized in more depth. There is optimism that the refined approach used by the ETSP contract site, wherein etiologically relevant models that include those with spontaneous seizures are used, will identify novel, potentially disease modifying therapies for people with pharmacoresistant epilepsy and those at risk for developing epilepsy. This article is part of the special issue entitled 'New Epilepsy Therapies for the 21st Century – From Antiseizure Drugs to Prevention, Modification and Cure of Epilepsy'. Highlights: The Epilepsy Therapy Screening Program (ETSP) is currently focused on identifying therapies for pharmacoresistant epilepsy. The pharmacological profile of antiseizure drugs (ASDs) in models incorporated into the refined workflow are described. Etiologically relevant models may identify novel therapies for people with pharmacoresistant epilepsy.